The Indian Glivec calculus: what changed for pharma after the hype

Hyperbolists think that the decision of the Indian Supreme Court to reject Novartis' Glivec (imatinib mesylate) patent claim has changed the face of the pharma market in India and perhaps in other emerging pharma nations, too1. But calmer calculus makes it clear that everything is not quite that dramatic.